Price T Rowe Associates Inc. MD Increases Stock Position in OPKO Health, Inc. (NASDAQ:OPK)

Price T Rowe Associates Inc. MD lifted its holdings in shares of OPKO Health, Inc. (NASDAQ:OPK) by 4.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 455,521 shares of the biotechnology company’s stock after buying an additional 18,571 shares during the quarter. Price T Rowe Associates Inc. MD owned about 0.07% of OPKO Health worth $670,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of OPK. Barclays PLC lifted its stake in shares of OPKO Health by 154.5% during the 3rd quarter. Barclays PLC now owns 543,336 shares of the biotechnology company’s stock valued at $810,000 after buying an additional 329,870 shares in the last quarter. PFG Investments LLC lifted its stake in OPKO Health by 9.4% in the 4th quarter. PFG Investments LLC now owns 1,160,885 shares of the biotechnology company’s stock worth $1,707,000 after purchasing an additional 99,795 shares in the last quarter. Capital Advisors Inc. OK purchased a new stake in OPKO Health in the 4th quarter worth approximately $220,000. Ieq Capital LLC purchased a new stake in OPKO Health in the 4th quarter worth approximately $52,000. Finally, Y Intercept Hong Kong Ltd purchased a new stake in OPKO Health in the 4th quarter worth approximately $102,000. 64.63% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have issued reports on the stock. StockNews.com cut shares of OPKO Health from a “hold” rating to a “sell” rating in a research note on Monday, May 5th. HC Wainwright reiterated a “buy” rating and issued a $3.00 target price on shares of OPKO Health in a research note on Monday, April 7th. Barrington Research reiterated an “outperform” rating and issued a $2.25 target price on shares of OPKO Health in a research note on Thursday, May 1st. Finally, JPMorgan Chase & Co. assumed coverage on shares of OPKO Health in a research note on Friday, April 25th. They issued a “neutral” rating on the stock. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $2.75.

Insider Activity

In other OPKO Health news, CEO Phillip Md Et Al Frost bought 200,000 shares of OPKO Health stock in a transaction that occurred on Monday, March 17th. The shares were bought at an average price of $1.74 per share, with a total value of $348,000.00. Following the acquisition, the chief executive officer now owns 213,501,448 shares in the company, valued at approximately $371,492,519.52. This trade represents a 0.09% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In the last quarter, insiders have purchased 767,434 shares of company stock worth $1,238,312. 49.69% of the stock is currently owned by corporate insiders.

OPKO Health Stock Performance

OPKO Health stock opened at $1.26 on Tuesday. The firm’s fifty day moving average price is $1.55 and its 200-day moving average price is $1.56. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97. The stock has a market cap of $999.25 million, a P/E ratio of -6.63 and a beta of 1.42. OPKO Health, Inc. has a fifty-two week low of $1.19 and a fifty-two week high of $2.04.

OPKO Health (NASDAQ:OPK) last posted its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.03). The company had revenue of $149.90 million for the quarter, compared to analysts’ expectations of $163.13 million. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. The business’s quarterly revenue was down 13.7% compared to the same quarter last year. During the same quarter last year, the business posted ($0.12) EPS. On average, equities research analysts expect that OPKO Health, Inc. will post -0.25 earnings per share for the current fiscal year.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.